Objective psychometric tests in clinical trials of dementia drugs: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Alzheimer Disease and Associated Disorders

Volumn 11, Issue SUPPL. 3, 1997, Pages 34-38

  Ferris, Steven H ^a,i   Lucca, Ugo ^b   Mohs, Richard ^c   Dubois, Bruno ^d   Wesnes, Keith ^e   Erzigkeit, Hellmut ^f   Geldmacher, David ^g   Bodick, Neil ^h  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Groupe Hospitalier   (France)

^e Cognitive Drug Research Ltd ^*  (United Kingdom)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ Aging and Dementia Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DEMENTIA; GERIATRIC ASSESSMENT; HUMAN; INTERNATIONAL COOPERATION; NEUROPSYCHOLOGICAL TEST; PRACTICE GUIDELINE; PSYCHOMETRY; REPRODUCIBILITY; STATISTICS; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS; DEMENTIA; GERIATRIC ASSESSMENT; HUMANS; INTERNATIONAL COOPERATION; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PRACTICE GUIDELINES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0030626838     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Ayre G, McKeith IG, Wesnes K, Sahgal V. Psychological function in dementia with Lewy bodies and senile dementia of the Alzheimer's type. Neurobiol Aging 1996;4S:205-6.
2. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
3. Brazzelli M, Capitani E, Della SS, Spinnler H, Zuffi M. A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan Overall Dementia Assessment. J Neurol Neurosurg Psychiatry 1994;57:1510-7.
4. Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988;24:689-92.
5. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, 1997.
6. Erzigkeit H. The SKT - a short cognitive performance test as an instrument for the assessment of clinical efficacy of cognition enhancers. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 1989:164-74.
7. Ferris SH, Flicker C, Reisberg B. NYU computerized test battery for assessing cognition in aging and dementia. Psychopharmacol Bull 1988;24:699-702.
8. Flicker C. Neuropsychological evaluation of treatment effects in the elderly: a critique of tests in current use. Psychopharmacol Bull 1988;24:535-56.
9. Kameyama M, Ito E, Otomo E, et al. Guidelines for clinical evaluation for cerebral circulation and metabolism improvers. In: Kyokai NK, ed. Evaluation of new drugs guidelines. Tokyo: Yakugyo Nippo Sha, 1995:17-41.
10. Kluger A, Ferris SH. Scales for the assessment of Alzheimer's disease. Psychiatr Clin North Am 1991;14:309-27.
11. Larrabee GJ, Crook T. A computerized everyday memory battery for assessing treatment effects. Psychopharmacol Bull 1988;24:695-7.
12. Leber P. Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, MD: US. Food and Drug Administration, 1990a.
13. Leber P. FDA letter to sponsors recommending use of CIBIC in dementia trials. Rockville, MD: US. Food and Drug Administration, 1990b.
14. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellack R, Karasu B, eds. Geriatric psychiatry. New York: Grune & Stratton, 1976:77-121.
15. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 1995;22:1-8.
16. Mohr E, Walker D, Randolph C, Sampson M, Mendis T. The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Int J Psychogeriatr 1996;11:397-411.
17. Mohs RC, Cohen L. Alzheimer's disease assessment scale (ADAS). Psychopharmacol Bull 1988;24:627-8.
18. Mohs RC, Knopman D, Peterson RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 1997;11 (Suppl 2):S13-21.
19. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-65.
20. Nicholl CG, Lynch S, Kelly CA, et al. The Cognitive Drug Research computerized assessment system in the evaluation of early dementia - is speed of the essence? Int J Geriatr Psychiatry 1996;10:199-206.
21. Raskin A, Niederhe G. Assessment in diagnosis and treatment of geriatric patients. Psychopharmacol Bull 1988;24:501-810.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;14:1356-64.
23. Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand 1993;149:26-8.
24. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GR. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95-102.
25. Wesnes KA. The pathology of attention of the dementias. J Psychopharmacol 1996;10(Suppl):A51.
26. Wesnes K, Simpson PM, Christmas L. The assessment of human information processing abilities in psychopharmacology. In: Hindmarch I, Stonier PD, eds. Human psychopharmacology: measures and methods. Vol. 1. Chichester, UK: Wiley, 1987:79-92.